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Abstract: Vitamin D3 has many important health benefits. Unfortunately, these benefits are not
widely known among health care personnel and the general public. As a result, most of the world’s
population has serum 25-hydroxyvitamin D (25(OH)D) concentrations far below optimal values.
This narrative review examines the evidence for the major causes of death including cardiovascular
disease, hypertension, cancer, type 2 diabetes mellitus, and COVID-19 with regard to sub-optimal
25(OH)D concentrations. Evidence for the beneficial effects comes from a variety of approaches
including ecological and observational studies, studies of mechanisms, and Mendelian randomization
studies. Although randomized controlled trials (RCTs) are generally considered the strongest form of
evidence for pharmaceutical drugs, the study designs and the conduct of RCTs performed for vitamin
D have mostly been flawed for the following reasons: they have been based on vitamin D dose
rather than on baseline and achieved 25(OH)D concentrations; they have involved participants with
25(OH)D concentrations above the population mean; they have given low vitamin D doses; and they
have permitted other sources of vitamin D. Thus, the strongest evidence generally comes from the
other types of studies. The general finding is that optimal 25(OH)D concentrations to support health
and wellbeing are above 30 ng/mL (75 nmol/L) for cardiovascular disease and all-cause mortality
rate, whereas the thresholds for several other outcomes appear to range up to 40 or 50 ng/mL. The
most efficient way to achieve these concentrations is through vitamin D supplementation. Although
additional studies are warranted, raising serum 25(OH)D concentrations to optimal concentrations
will result in a significant reduction in preventable illness and death.
Keywords: Alzheimer’s disease; cancer; cardiovascular disease; COVID-19; diabetes; hypertension;
Mendelian randomization; vitamin D; 25-hydroxyvitamin D
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1. Introduction
Vitamin D deficiency is the most common nutritional deficiency in the world, although
vitamin D is one of the most well understood compounds. It reduces risks of many adverse
health outcomes through both genetic and non-genetic mechanisms; it is readily available
from supplements, is safe, and inexpensive. There are over 94,000 publications on vitamin
D listed on pubmed.gov as of 20 December 2021. Despite all this, vitamin D deficiency
(25-hydroxyvitamin D (25(OH)D) concentration <20 ng/mL) is very common, affecting
about half of the world’s population [1], whereas the higher concentrations necessary for
optimal non-skeletal health (25(OH)D >30 ng/mL) are not so common. The reason for
this is that the beneficial effects of vitamin D for non-skeletal disorders have only received
widespread research attention since 2000. Furthermore, methods for studying the many
health effects of vitamin D have been evolving and researchers have had to identify their
various strengths and limitations. Another factor is that conventional medicine in most
countries generally focuses on treatment rather than on the prevention of disease.
This is a narrative review of what is known about the role of vitamin D supplementation and how it raises serum 25(OH)D concentration and influences health outcomes
as well as achieves maximum reductions of mortality rates in developed countries from
the commonest fatal diseases (e.g., cancer, cardiovascular disease including hypertension,
COVID-19 and diabetes mellitus type 2). In addition, an overview is included of the
types of studies used to evaluate the effects of vitamin D supplementation, and of the
different serum 25(OH)D concentrations required to achieve various health outcomes,
with outlines of the strengths and limitations of the various types of studies. Circulating
25(OH)D is important as the precursor of the most active vitamin D metabolite, calcitriol
(1,25-dihydroxyvitamin D) formed by the 1-alpha hydroxylation of 25(OH)D in the kidneys
and many other immune and metabolically active tissues as needed.
The approach taken in this report is to base recommendations on the strongest evidence available, generally from observational studies that are supported by other types
of studies. The strengths and weaknesses of the various types of studies, ranging from
ecological studies to meta-analyses of randomized controlled trials (RCTs) and Mendelian
randomization (MR) studies are discussed at the end of the discussion. Although metaanalyses are often considered to be stronger evidence than individual studies, the fact that
many studies have flaws in their design, conduct, or analysis, means that some individual
studies are better suited for making recommendations than many meta-analyses.
The background for the present report is provided by data on mortality rates for major
causes of death in 2016 by the World Health Organization (see Table 1 for Germany, Japan,
Saudi Arabia, and the U.S.). This study will concentrate on the diseases with the highest
prevalence or mortality rates.
It is apparent from the data in Table 1 that there are large differences in mortality rates
by country and sex. National diet plays an important role in health outcomes. Spending on
health care can affect outcomes. Obesity increases adverse health outcomes. Smoking has
many adverse health effects. Males tend to smoke more than females, and this may explain
why mortality rates for males are higher than for females. Although we do not discuss the
effect of factors other than vitamin D and solar UVB in this study, we acknowledge that
raising serum 25(OH)D concentrations may not have the same effects in all participants.
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Table 1. Mortality rates (deaths/100,000/year) as well as obesity rates in 2016.

Outcome

Germany
M

Germany
F

Japan
M

Japan
F

Saudi
Arabia
M

Saudi
Arabia
F

USA
M

USA
F

All causes

504

328

401

217

777

608

592

404

CVD

160

106

93

54

329

261

167

104

IHD

95

54

42

22

219

154

106

56

Stroke

24

20

33

20

86

76

24

21

Cancer

148

97

139

76

64

57

132

99

Breast

0.2

19

0.1

10

0

9

0.2

18

Lung

36

17

33

10

7

3

33

23

COPD

26

15

19

7

15

12

35

28

Lower respiratory tract disease

12

7

36

17

46

42

13

10

Diabetes mellitus

12

8

5

2

30

25

19

12

Alcohol abuse

7

2

0.5

0.1

0.5

0.1

4

1

Alzheimer’s disease

15

16

6

5

46

44

28

35

Obesity (%) – 2016

22

4

35

36

Table 1. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016. Geneva,
World Health Organization; 2018. Obesity data from https://obesity.procon.org/global-obesity-levels/ (accessed
on 15 December 2021). COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; F, female;
IHD, ischemic heart disease; M, male.

2. Results
2.1. Cardiovascular Disease
Robert Scragg was the first to propose that the adequate provision of vitamin D
might reduce the risk of cardiovascular disease (CVD) since incidence and mortality rates
were highest in winter when solar UVB doses and serum 25(OH)D concentrations were
lowest [2]. Markedly higher rates of CVD risk factors were found in winter than in summer
in 24 population-based studies in 14 countries [3]. The risk factors considered included
BMI, waist circumference systolic and diastolic blood pressure, total, high- and low-density
lipoprotein cholesterol, triglycerides, and glucose levels.
Thomas Wang and colleagues published the first observational study of CVD risk
with respect to serum 25(OH)D concentration in a prospective study of participants in the
Framingham Offspring Study in 2008 [4]. Several vitamin D-related mechanisms appear to
have protective roles for CVD including the known inhibition of vascular smooth muscle
proliferation, the suppression of vascular calcification, the reduction of inflammation
through the regulation of cytokines, and the regulation of blood volume and systemic
vascular resistance through renin gene suppression [5].
Observational studies have shown that serum 25(OH)D concentrations correlate inversely with CVD incidence and mortality rates and also with data for coronary or ischemic
heart disease, congestive heart failure and stroke. Acute cardiovascular events are commonly precipitated by plaque disruption following local inflammation and the release of
destructive MMPs, especially MMP9, from invading foam macrophages. Inflammation is
suppressed by vitamin D and non-skeletal MMP2/9 production is suppressed by vitamin
D; circulating MMP2/9 concentrations relate inversely to serum 25(OH)D and can be
suppressed by modest supplementation [6].
In clinical trials, vitamin D supplementation has been found to reduce the serum levels
of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides
(TG) but not high-density lipoprotein cholesterol (HDL-C) [7].
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A study of 20,025 patients in the U.S. Veterans Health Administration system followed for 20 years found that those with no previous myocardial infarction (MI) who had
basal 25(OH)D concentrations ≤20 ng/mL and raised their concentrations to >20 ng/mL
significantly reduced their risk of MI [8]. For those achieving 25(OH)D concentrations
≥30 ng/mL vs. 21 to 29 ng/mL, the hazard ratio (HR) for MI was 0.65 (95% CI, 0.49 to
0.85, p = 0.002), whereas for those who achieved 25(OH)D concentrations ≥30 ng/mL vs.
≤20 ng/mL, the HR for MI was 0.73 (95% CI, 0.55 to 0.96, p = 0.02).
Similarly, a study based on UK Biobank participants who had CVD followed for a
median of 11.7 years showed a linear inverse association of CVD mortality (P-non-linearity
= 0.07) with 25(OH)D, the adjusted HR decreasing from 1.31 (95% CI, 1.14 to 1.43) at
4 ng/mL to 0.83 (95% CI, 0.77 to 0.88) at 15 ng/mL and then (linearly) to 0.37 (95% CI, 0.22
to 0.62) at 60 ng/mL [9].
Support for the role of vitamin D in reducing the risk of CVD also comes from observational associations and MR analyses of four population-based cohort studies (UK Biobank,
EPIC-CVD and two Copenhagen population-based studies) comprising 386,406 middleaged individuals of European ancestries [10] followed after enrollment, with blood drawn
from between 9 to 21 years. In the observational part of this study, coronary heart disease
events were significantly increased below 12 ng/mL, stroke events below 20 ng/mL, and
the CVD mortality rate below 25 ng/mL. In that MR analysis, a 4 ng/mL increase in genetically predicted 25(OH)D was associated with an OR for stroke of 0.85 (95% CI, 0.70 to 1.02,
p = 0.09) and for coronary heart disease of 0.89 (95% CI, 0.76 to 1.04, p = 0.14). However,
these values probably underestimate the true value due to changes in 25(OH)D over time.
An analysis of HR vs. the follow-up period for observational studies of all-cause mortality
rate for an 8 ng/mL difference in 25(OH)D concentration over six to fourteen years found a
linear increase in HR from 0.81 (95% CI, 0.67 to 1.02) at six years to 0.96 (95% CI, 0.9 to 1.01)
at fourteen years [11].
Subsequently, an MR study based on UK Biobank data for 20,805 incident CVD
events amongst 267,980 subjects with both serum 25(OH)D concentration data and phenotypic 25(OH)D analyses [12] reported that each 4 ng/mL increase in phenotypic 25(OH)D
was associated with a 1.6% lower risk of a CVD event (OR = 0.98 (95% CI, 0.98 to 0.99,
p = 0.0001)) for 25(OH)D concentrations of up to 50 ng/mL. However, the genetic (MR)
analysis using data for 35 vitamin D-related single nucleotide polymorphisms (SNPs) found
in the 295,788 participants including 44,519 CVD cases, revealed that there was an L-shaped
relationship, with 11% (95% CI, 1.05 to 1.18) higher odds for CVD events at 10 ng/mL than
at 20 ng/mL; moreover, for 25(OH)D concentrations around 4 ng/mL, the odds were +2.3
(95% CI, 1.6 to 3.7) using the non-linear analytical approach of Staley and Burgess [13] on
the 25(OH)D data after the data had been divided into 100 equal strata, with a plateau
above ~20 ng/mL.
2.2. Hypertension
Good evidence now shows that vitamin D status affects the risk and prevalence
of hypertension. For example, a meta-analysis of seven out of eight prospective cohort
studies with 283,537 participants found the risk of developing hypertension for those in
the upper third vs. lower third of 25(OH)D concentrations was reduced by 30% (RR = 0.70
(95% CI, 0.58 to 0.86)) [14] with an overall RR for incident hypertension for every 10 ng/mL
increment in baseline 25(OH)D concentration of 0.88 (0.81, 0.97) using dose-response
analysis.
An MR study on 142,225 participants of European descent from several countries with
measurements of systolic and diastolic blood pressure and genetic analyses [15] found
four variants of genes affecting 25(OH)D synthesis from vitamin D (CYP2R1) through
involvement in the synthesis of 7-dehydrocholesterol, which is converted to vitamin D3
in the skin via UVB irradiance followed by a thermal process involving DHCR7, the gene
providing instructions for making an enzyme called 7-dehydrcholesterol reductase. In their
meta-analysis, a ’synthesis score’ was associated with a reduced risk of hypertension (OR
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per allele, 0.98, 0.96–0.99; p = 0.001). Each 10% increase in genetically determined 25(OH)D
concentration was associated with a reduction of −0.29 mm Hg in diastolic blood pressure
(95% CI, −0.52 to −0.07; p = 0.01), of −0.37 mmHg in systolic blood pressure (95% CI, −0.73
to 0.003; p = 0.052), and an 8% decreased risk of hypertension (OR 0.92, 95% CI, 0.87–0.97;
p = 0.002). Although these differences in blood pressure were small, that was likely due to
the limitations of the MR analyses which had few alleles of genes affecting serum 25(OH)D
concentrations to consider.
An observational study of community-based participants taking ~4000 IU/day of
vitamin D3 to achieve 25(OH)D concentrations >40 ng/mL reported significant reductions
in blood pressure and hypertension prevalence after a year [16]. At baseline, 592 participants (7.3%) were hypertensive. At follow-up (12 ± 3 months), 71% of them were no
longer hypertensive. The mean 25(OH)D concentration for those hypertensive participants
increased from 33 ± 16 ng/mL to 45 ± 14 ng/mL with increased vitamin D supplementation (from ~2000 IU/day to ~6000 IU/day). For those not taking hypotensive medication,
systolic BP decreased by 18 ± 19 mmHg and diastolic BP fell by 12 ± 12 mmHg, whereas
in those taking hypotensive medication after joining the program, systolic BP decreased by
14 ± 21 mmHg and diastolic BP decreased by 12 ± 12 mmHg, whereas there were no
changes in blood pressure in the normo-tensive control participants.
2.3. Cancer
It was first proposed in 1980 that sunlight reduced the risk of colon cancer with vitamin
D production being the likely reason [17]. Since then, numerous ecological studies have
reported that solar UVB dose indices correlate inversely with incidence and/or mortality
rates for nearly 20 types of cancer [18–20]. The best ecological studies are those from single
mid-latitude countries where variations in solar UVB doses tend to be large [21,22], whereas
variations in other risk-modifying factors (diet, skin pigmentation, dress, obesity, smoking,
alcohol consumption, etc.) are often small or can be accounted for [19]. Thus, ecological
studies provide a case for examining whether better vitamin D provision reduces cancer
incidence or cancer mortality.
Observational studies have shown associations between cancer risk and solar UV
radiation. A meta-analysis of 14 studies observed reduced breast cancer rates for those
spending ≥1 h/day in sunlight during summer months over their lifetime or adulthood
compared to <1 h/day (RR = 0.84; 95% CI: 0.77, 0.91) [23]. Another meta-analysis of six
studies between 2005 and 2020 found an inverse correlation between exposure to solar UV
radiation and breast cancer risk (RR: 0.70, 95% CI: 0.65, 0.75), [24]. In total, 17 case-control
studies and 9 cohort studies, including 216,285 non-Hodgkin’s lymphoma (NHL) and
23,017 Hodgkin’s lymphoma (HL) patients, were included in the final analysis. Personal
sunlight exposure was significantly associated with reduced risks of HL (OR = 0.77; 95%
CI 0.68–0.87) and of all types of NHL (OR = 0.81; 95% CI 0.71–0.92) other than T-cell
lymphoma [25]. Furthermore, no mechanism other than the production of vitamin D has
been suggested to explain the protective effects of solar UV against cancer.
There are many observational studies of cancer incidence with serum 25(OH)D concentrations. The meta-analyses of observational studies are shown in Table 2. The reason
case-control studies report greater risk reductions is probably the long follow-up times of
cohort studies providing baseline 25(OH)D concentrations which become less well correlated with cancer outcomes over time [26]. Although serum 25(OH)D concentration can be
reduced by acute inflammatory illness [27], cancer does not appear to have this effect.
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Table 2. Meta-analyses of observational studies of individual cancer site risks in relation to serum
25(OH)D concentrations #.

Cancer Site

N Studies

Type of Study

RR
(95% CI)
(High vs. Low)

Reference

Bladder

5

Cc

0.70 (0.56 to 0.88)

[28]

Bladder

2

Cohort

0.80 (0.67 to 0.94)

[28]

Breast

44

Cc

0.57 (0.48 to 0.66)

[29]

Breast

6

Cohort

1.17 (0.92 to 1.48)

[29]

Colorectal

11

Cc

0.60 (0.53 to 0.68) *

[30]

Colorectal

6

Cohort

0.80 (0.66 to 0.97) *

[30]

(*) fixed effects model; # https://pubmed.ncbi.nlm.nih.gov/ (accessed on 15 December 2021).

Although the data in Table 2 demonstrate that serum 25(OH)D concentration is commonly inversely correlated with cancer incidence, they do not provide data on the relationship of 25(OH)D concentration to cancer incidence, although other studies do so.
For breast cancer, two studies can be used. One is a meta-analysis of 36 case-control and
four cohort studies [29] where a spline fit to the data reveals a 60% (95% CI, 45% to 70%)
reduction in risk with 25(OH)D concentrations from 4 ng/mL up to 40 ng/mL and an 80%
reduction with 25(OH)D concentrations of up to 80 ng/mL. However, the primary data
source for 25(OH)D concentrations of >40 ng/mL is from an observational study based on
data from women enrolled in vitamin D RCTs who took vitamin D supplements (1000 or
2000 IU/day) or a placebo [31,32] or were enrolled in a volunteer cohort who took doses
of their choice and had serum 25(OH)D measured half-yearly [33]. This pooled cohort
included 5028 women out of whom 77 developed incident breast cancer. There was an 82%
lower incidence rate for 25(OH)D concentrations >60 ng/mL vs. <20 ng/mL (p = 0.006)
and, importantly, the slope of that relationship was similar for subjects with values both
below and above 40 ng/mL.
For colorectal cancer, a 2019 meta-analysis [34] using data from case-control studies of
women with 25(OH)D concentrations between <15 ng/mL and >29 ng/mL found that the
relative risk (RR) per 10 ng/mL increase in 25(OH)D was 0.81 (95% CI, 0.75 to 0.87), whereas
for men with 25(OH)D concentrations between <16 and >30 ng/mL, the RR was 0.93 (95%
CI, 0.86 to 1.00). Thus, for rises in 25(OH)D ranging from ~10 ng/mL to ~35 ng/mL, the RR
was 0.59 for women and 0.83 for men. The increase in RR seen with 25(OH)D concentrations
of >100 ng/mL vs. <40 ng/mL is likely due to participants starting to supplement shortly
prior to enrolling in cohort studies [35] and should not necessarily be taken to indicate
that higher 25(OH)D concentrations reverse the beneficial effects found at lower 25(OH)D
concentrations, especially since the ecological study of cancer mortality rates in the U.S.
between 1950 and 1994 showed that UVB dose–cancer mortality rate curves plateaued at
the highest UVB exposures [36].
The effect of vitamin D in reducing cancer mortality rates appears to be more significant
than for reducing cancer incidence. For example, the VITamin D and OmegA-3 TriaL
(VITAL) study conducted by Harvard University [37] did not find a significant reduction
in all-cancer incidence with vitamin D supplementation vs. placebo for the entire set of
participants but did find a significantly reduced risk of mortality when the first two years
of data were omitted, HR = 0.75 (0.59–0.96). Furthermore, another analysis of vitamin D
RCTs also found a greater reduction for mortality rates than for incidence rates (Table 3).
However, meta-analyses of observational studies found significant reduction for both
all-cancer incidence and mortality rates (Table 4).
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Table 3. Meta-analyses of breast cancer risk from vitamin D RCTs.
Cancer Site

N Studies

Outcome

RR
(95% CI)

Reference

Breast

9

Incidence

0.96 (0.86 to 1.07)

[38]

Breast

5

Mortality

0.87 (0.79 to 0.96)

[38]

Table 4. Meta-analyses of cancer incidence and mortality rates from observational studies.

Cancer Site

N Studies

Outcome

Low, High
25(OH)D
(ng/mL)

RR
Low
25(OH)D

RR
High
25(OH)D

Ratio
High to Low

Reference

Total

8

Incidence

1, 21

1.31 (95% CI,
0.87 to 2.05)

0.71 (95% CI,
0.55 to 0.92)

0.54

[39]

17

Mortality

10, 40

1.47 (95% CI,
1.11 to 1.88)

0.87 (95% CI,
0.75 to 1.02)

0.59

[39]

Additional support for the effects of vitamin D provision on cancer risks is that many
mechanisms exist through which vitamin D reduces cancer risks, including effects on cells
that are anti-proliferative, pro-differentiating, anti-inflammatory, immunomodulatory, antiangiogenic around tumors, and anti-metastatic [40–43]. The active vitamin D metabolite
(1α,25-dihydroxyvitamin D3 or calcitriol) inhibits proliferation and promotes the epithelial
differentiation of human colon carcinoma cell lines that express the vitamin D receptor
(VDR) via the regulation of a large number of genes [44]. Other RCTs reported that the
higher the vitamin D supplement given (up to 10,000 IU/day), the more genes whose
expression is changed [45,46]. No adverse effects of supplementation with 10,000 IU/day
were found in these studies. Thus, the known mechanisms support the finding that a higher
25(OH)D threshold can reduce cancer risks and cancer mortality.
Most vitamin D–cancer RCTs seem to have failed because they were designed using
guidelines developed for assessing pharmaceutical drugs, not nutrients [47,48]. As a result,
baseline 25(OH)D concentrations were often too high and vitamin D doses were generally
too low to correct deficiency. Furthermore, changes in serum 25(OH)D concentrations differ
individually in response to supplementation [49], and other sources of vitamin D, including
unknown intakes from self-supplementation in both treatment and placebo arms, cannot
be allowed for.
A meta-analysis of vitamin D RCTs regarding breast cancer incidence included eight
trials comprising 72,275 participants with median follow-up periods ranging from 1 to
11.9 years. The doses were 400 to 1100 IU/day in four trials, 2000 IU/day in two trials, and
100,000 IU/month in two trials. This study found RRs of 1.04 (95% CI 0.85–1.29, p = 0.68)
for vitamin D supplementation (6 trials, 33,472 participants, 246 events), and 0.99 (95% CI
0.91–1.07, p = 0.73) for vitamin D plus calcium (4 trials, 41,957 participants, 2195 events) [50].
The doses were too low and/or too infrequent in the trials of monthly dosing since the
half-life of 25(OH)D is about 20 days; thus, it is not surprising that the RR findings were
not significant.
The inspection of VITAL study results, where the mean baseline and achieved 25(OH)D
concentrations for those with measured values were 27.8 and 39.7 ng/mL for males and
31.7 and 43.6 ng/mL for females, and using a vitamin D3 dose of 2000 IU/d, the HR for
overall cancer incidence was 0.96 (95% CI, 0.88 to 1.06). However, for black participants,
where the mean reported baseline and achieved 25(OH)D concentrations were 25.0 and
39.7 ng/mL, respectively, the HR was 0.77 (95% CI, 0.59 to 1.01) and for participants with a
BMI <25 kg/m2 with a mean reported baseline and achieved 25(OH)D concentrations of
33.3 and 45.9 ng/mL, respectively, the HR for cancer incidence was 0.76 (95% CI, 0.63 to
0.90) [37].
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In conclusion, the evidence that higher vitamin D status reduces the risk of cancer
incidence includes:
1—Single-country ecological studies finding that about 20 types of cancer have incidence and mortality rates inversely correlated with various indices of solar UVB doses.
2—Observational studies reporting that several types of cancer have incidence rates
inversely correlated with serum 25(OH)D in case-control or cohort observational studies.
3—An observational study using individual participant data for women taking vitamin
D or placebo in two RCTs or taking vitamin D in a volunteer cohort, and with some
subjects achieving 25(OH)Ds > 60 ng/mL, achieving a significant reduction in breast cancer
incidence.
4—Mechanisms that explain how vitamin D reduces the risk of cancer incidence,
progression, and metastasis.
5—No mechanisms are yet known that might explain how non-vitamin D mechanisms
associated with UVB exposure could reduce the risk of cancer.
2.4. Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) is a condition in which there is too much glucose
circulating in the blood because of long-standing increases in insulin resistance leading
to the eventual deficiency in insulin responsiveness to hyperglycaemia [51,52]. Although
T2DM is generally associated with obesity and ‘cafeteria’ diets, there is now reasonably
strong evidence that risk is inversely associated with serum 25(OH)D concentration and
that correcting vitamin D deficiency over time can reduce T2DM risks.
The mechanisms by which vitamin D reduces the risk of T2DM include β-cell insulin
release through a rise in intracellular calcium concentration [53] and by stimulating insulin
synthesis [54], which was reported in 1980 [55] (see review in [56]). Vitamin D reduces
insulin resistance by reducing oxidative stress and inflammation and reducing both hepatic
lipogenesis and hepatic glucose release through metformin-like effects [57,58] and by
promoting increased metabolic efficiency in skeletal muscle [59,60]. Thus, it is not surprising
that obesity, which is marked by increased systemic inflammation as well as lower 25(OH)D
concentrations [61], and a lack of physical activity are major risk factors for T2DM [62].
Prospective observational studies support a role for vitamin D in reducing T2DM
risks. A meta-analysis of 16 prospective studies published in 2013 found an OR = 1.50
(95% CI, 1.33 to 1.67) for the incidence of T2DM for low vs. high 25(OH)D status in each
study [63]. Large prospective studies have shown that lower 25(OH)D status is a risk factor
for metabolic syndrome [64] and for T2DM [65].
Higher 25(OH)D concentrations are associated with lower mortality rates for adults
with diabetes prospectively. A study was reported on 6329 adults with diabetes from the
Third National Health and Nutrition Examination Survey (NHANES III) and NHANES
2001–2014 followed up through 31 December 2015 [66]. In 55,126 person-years of follow-up,
2056 deaths were documented (605 from CVD and 309 from cancer). Compared with
participants with 25(OH)D concentrations <25 nmol/L, the multivariate-adjusted HRs and
95% CI for participants with 25(OH)D concentrations >75 nmol/L were 0.59 (95% CI, 0.43,
0.83) for all-cause mortality (ptrend = 0.003), 0.50 (95% CI, 0.29, 0.86) for CVD mortality
(ptrend = 0.02), and 0.49 (95% CI, 0.23, 1.04) for cancer mortality (ptrend = 0.12).
A meta-analysis of 24 RCTs (n = 1528 individuals with T2DM) found significant
reductions in glycosylated hemoglobin (HbA1c) (mean difference: −0.30%; 95% CI: −0.45
to −0.15, p < 0.001), serum fasting plasma glucose (FPG) (mean difference: −4.9 mg/dL
(−0.27 mmol/L); 95% CI: −8.1 to −1.6 (−0.45 to −0.09 mmol/L), p = 0.003), and the
homeostatic model assessment of insulin resistance (HOMA-IR) (mean difference: −0.66;
95% CI: −1.06 to −0.26, p = 0.001) in diabetic patients [67] where a mean increase in
25(OH)D concentration in those RCTs was 17 ± 2 ng/mL, suggesting that a minimum dose
of 4000 IU/day of vitamin D is advisable for improving insulin sensitivity and glycemic
control in T2DM patients.
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It seems that vitamin D supplementation in doses of 4000 IU/day or higher improved
the manifestation of diabetic complications. An example would be the study conducted in
St. Petersburg, Russia that included 62 T2DM patients with diabetic polyneuropathy [68].
The intake of 40,000 IU/week of vitamin D for 24 weeks was associated with an increased
25(OH)D concentration from 16 to 72 ng/mL and a reduction in neurological deficit and
pain severity, as well as improved interleukin profiles and markers for microcirculation. No
overall changes were detected in T2DM patients who received 5000 IU/week of vitamin D.
The Vitamin D and Type 2 Diabetes (D2d) Study conducted by Tufts University is the
largest RCT to examine the effect of vitamin D supplementation on the risk of T2DM [69].
A total of 2423 prediabetic participants were enrolled and half were given 4000 IU/day of
vitamin D3 , whereas the other half were given a placebo during a mean 2.5-year follow-up
period. The HR for progression to T2DM for the treatment arm compared to the control
arm was 0.88 (95% CI, 0.75 to 1.04, p = 0.12). Two subgroups had a significantly reduced risk
when comparing treatment to control groups, those with BMI <30 kg/m2 (HR = 0.71 (95%
CI, 0.53 to 0.95)) and those not taking calcium (HR = 0.81 (95% CI, 0.66 to 0.98)). However,
it was a secondary analysis related to 25(OH)D concentration maintained through the RCT
that provided strong support for vitamin D supplementation reducing the progression
from pre-diabetes to T2DM [70]. Over the range from 20–30 ng/mL to >50 ng/mL, for
each increase in 25(OH)D by 10 ng/mL, those in the treatment arm had an HR of 0.75 (95%
CI, 0.68 to 0.82) for conversion to T2DM. Therefore, secondary analysis based on serum
25(OH)D concentration is clearly an appropriate way to analyze RCT results since vitamin
D, being a nutrient provided from several sources, has non-linear effects in contrast to a
‘medication’ [47,48].
2.5. COVID-19
The world is in the midst of the COVID-19 pandemic with nearly 5.6 million deaths reported to date (21 January 2022) (https://www.worldometers.info/coronavirus/ (accessed
on 5 January 2022)). On 2 April 2020, it was suggested that vitamin D could reduce the risk
of COVID-19 through several mechanisms including inducing the secretion of cathelicidins
and defensins known to reduce viral replication rates and reduce the production of proinflammatory cytokines aggravating the inflammation that injures the lungs, leading to
pneumonia. Vitamin D also increases the secretion of anti-inflammatory cytokines, overall
reducing the risk of highly dangerous cytokine storms [71]. The important modulatory
effect of vitamin D on immune-related genes through binding to VDR implicates a potential
role in clearing SARS-CoV-2 infections [72].
The rationale for that suggestion included the observation that case fatality rates in
the U.S. during the 1918–1919 influenza pandemic were mainly due to the development
of pneumonia and were lowest in communities with the highest solar UVB doses [73].
In addition, a meta-analysis of RCTs had shown a reduction in acute respiratory tract
infections with supplementation in vitamin D deficiency cases using analyses of individual
participant data [74].
Observational studies suggest that vitamin D reduces SARS-CoV-2 infection risk.
A study of >190,000 patients who had SARS-CoV-2-positive tests in the U.S. between 9
March and 19 June 2020 and had their serum 25(OH)D concentration measured during the
previous twelve months (by Quest Diagnostics, Secaucus, NJ) [75] showed the following
results by race/ethnicity, after adjusting for seasonal differences: black non-Hispanics, Hispanics, and white non-Hispanics had ~19%, 16% and 9% rates for a 25(OH)D concentration
<20 ng/mL, respectively, and rates of 11%, 10%, and 5%, respectively for 25(OH)D values of
~55 ng/mL. These values represent reductions by about 40% for all three races/ethnicities.
The higher SARS-CoV-2 positivity rates for black American non-Hispanics and Hispanics
was mostly likely due to their being in lower socioeconomic strata and more likely to
be unable to socially isolate or to work from home than white non-Hispanics as well as
being more likely to have been aggravated by their lower vitamin D status, itself known to
worsen with lower SE status as well as being increased in those with darker skin [76].
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There have been many observational studies. Some were retrospective studies where
25(OH)D concentrations for those becoming ill and being diagnosed with COVID-19 were
obtained from measurements made before diagnosis (seasonally adjusted). Examples
include those from Israel [77] and Chicago, IL, USA [78,79]. However, the majority of such
observational investigations were based on 25(OH)D concentration at the time of diagnosis
upon hospital admission [80].
The most recent meta-analysis of COVID-19 risk in relation to serum 25(OH)D concentrations was published on 11 December 2021 [81]. It included results from 76 observational
studies. Vitamin D deficiency/insufficiency increased the odds of developing COVID19 (OR 1.46, 95% CI 1.28–1.65, p < 0.0001), developing severe disease (OR 1.90, 95% CI
1.52–2.38, p < 0.0001) and death (OR 2.07, 95% CI 1.28–3.35, p = 0.003). A major concern is
that having COVID-19 must itself lower 25(OH)D concentration as is usual in severe infection, as shown experimentally [27]. This concern will eventually be clarified by examining
data for COVID-19 outcomes by pre-illness and/or pre-pandemic 25(OH)D concentration
in comparison with those found at the time of diagnosis. In one meta-analysis of vitamin
D deficiency/insufficiency and risk of COVID-19 involving 19 studies, the OR was 1.46
(95% CI, 1.28 to 1.65). Of the 19 studies, ten had 25(OH)D concentrations measured prior
to COVID-19 diagnosis, of which three were 10–15 years before the pandemic. The ORs
for those three were near 1.00 and non-significant, as expected for such a long lag time.
Examining the five studies with values measured in the previous year (omitting one that is
a preprint), the ORs for four of them were above the mean value and one was very near
the meta-analysis value, 1.46. Thus, on the basis of that analysis, there does not seem to be
a significant difference between risks relating to low 25(OH)D values whether measured
before or at the time of COVID-19 diagnosis.
The most recent article on vitamin D and the risk of COVID-19 hospitalization and
mortality was published on 1 January 2022 [82]. It presented an analysis of 4599 veteran
patients receiving care in the US Department of Veterans Affairs health care facilities who
tested positive for SARS-CoV-2 during the period from 20 February to 8 November 2020
and who had serum 25(OH)D concentration data from the previous 15 to 90 days on file.
Twenty one percent of the patients were hospitalized and 7.4% died within 60 days of their
index SARS-CoV-2 test. Hospitalization rates decreased from 25% at 15 ng/mL to 18%
at 60 ng/mL (adjusted relative risk = 1.29 (95% CI, 1.06 to 1.57), whereas morality rates
decreased from 11% for vitamin D levels of 15 ng/mL to 6% at 60 ng/mL (adjusted relative
risk = 1.82 (1.27 to 2.63)).
Results of a trial conducted in Turkey involving 132 COVID-19 patients with a baseline
25(OH)D concentration <30 ng/mL, of whom 80 were treated with high-dose vitamin D3
to achieve a 25(OH)D concentration >30 ng/mL, was reported recently [83]. Vitamin D3
doses ranged from 224,000 to 500,000 IU over periods from three to 14 days. The mean
25(OH)D for the treated patients reached only 31 ± 12 ng/mL on day 7 and 35 ± 11 ng/mL
on day 14. The mortality rate was 11.2% (97 out of 867) in the whole cohort. The mortality
rate for patients who had comorbidities but received vitamin D treatment was 5.5% (9 out
of 162). Having vitamin D treatment decreased the 14-day mortality rate significantly (OR
for survival: 2.14, 95%CI: 1.06 to 4.33, p = 0.03).
Calcifediol (25(OH)D3 ) is being used in Spain to treat COVID-19 patients, its advantage being that it increases serum 25(OH)D concentrations within hours and much faster
than intact vitamin D3 . The first study of the calcifediol treatment of COVID-19 patients
was conducted in Cordoba, Spain [84] in 76 consecutive patients admitted to a university hospital with clinically diagnosed COVID-19 who all received standard care with
hydroxychloroquine plus azithromycin for patients with pneumonia (a broad-spectrum
antibiotic). Fifty of these patients were ‘randomized’ to receive oral calcifediol on the day
of admission at 0.532 mg followed by 0.266 mg on days 3 and 7 and then weekly until
discharge or intensive care unit (ICU) admission. Calcifediol is ~×3 times more effective in
raising serum 25(OH)D concentration (after adjusting for weight) than vitamin D3 . The
only significant difference in the prognostic factors for COVID-19 at baseline was previous
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high blood pressure (at 24% in the treatment group and 58% in the control group; p = 0.002).
Only one of the treated patients but 13 of the untreated patients required admission to the
ICU (p < 0.001). There was no death among treated patients, but two untreated patients
requiring care in the ICU died.
Another Spanish report summarized the results of treating 537 COVID-19 patients
admitted to any of the five hospitals in southern Spain between 5 February and 5 May 2020
with calcifediol (25(OH)D3 ) [85], excluding the 76 patients already mentioned [84]. In that
study, 79 patients were treated and 458 were not treated with calcifediol. The untreated
patients had significantly higher rates of CURB-65 ≥3 (21 vs. 8%) and ARDS (25 vs. 10%),
higher CRP (130 ± 100 vs. 100 ± 80 units) and blood urea nitrogen (22 ± 19 vs. 16 ±
15 units) values together with lower oxygen saturation at admission (93 ± 6% vs. 95 ± 4%).
However, those differences were not mortality rate determinants. The crude OR for death
in patients treated with calcifediol vs. those not so treated was 0.22 (95% CI, 0.08 to 0.61,
p < 0.01) and was 0.16 (95% CI, 0.03 to 0.80) after adjustment for all other risk factors. On the
other hand, higher age, ARDS, CURB-65 ≥3, cerebrovascular disease, COPD, cancer, and
ratio of neutrophils to lymphocytes were significantly associated with increased mortality.
Other studies have shown that low serum 25(OH)D concentration is a stronger marker of
adverse outcomes than those other factors. For example, in an observational study in Iran
involving 442 patients in general wards and 66 patients in the ICU, of whom 55 died, only
age (p < 0.001, albumin (p < 0.001), calcium, (p = 0.002) and serum 25(OH)D (p = 0.047))
were significantly associated with mortality in multivariate analysis, whereas BMI, diabetes
mellitus, hypertension, IHD, creatinine, and phosphorus were not [86].
Another review used meta-analyses on COVID-19 hospitalized patient outcomes [87].
Using two studies that gave vitamin D3 and two giving calcifediol, the OR for intensive
care unit admission was 0.27 (95% CI, 0.09 to 0.76); on the other hand, based on four studies
giving vitamin D3 and one giving calcifediol, the OR for needing mechanical ventilation
was 0.34 (95% CI, 0.16 to 0.72) with these treatments. Overall, from those eight studies plus
one more, the OR for mortality for any form of vitamin D/calcifediol treatment was 0.37
(95% CI, 0.21 to 0.66).
An observational study in Barcelona compared the incidence of COVID-19 for patients
with respect to serum 25(OH)D concentration and whether they were being treated with
vitamin D3 or calcifediol [88]. For those being treated with vitamin D3 and achieving
>30 ng/mL, the multivariate HR compared to untreated controls with <20 ng/mL for SARSCoV-2 infection was 0.66 (95% CI, 0.57 to 0.77), 0.72 (0.52 to 1.00) for severe COVID-19, and
0.66 (0.46 to 0.93) for COVID-19 mortality. Similarly, for those being treated with calcifediol,
the multivariate HR for SARS-CoV-2 infection was 0.69 (95% CI, 0.61 to 0.79), 0.61 (0.46
to 0.81) for severe COVID-19, and 0.56 (0.42 to 0.76) for COVID-19 mortality. The small
differences between vitamin D and calcifediol treatment may be due to different effective
vitamin D doses and achieved 25(OH)D concentrations. Thus, there is accumulating
evidence that higher serum 25(OH)D concentrations protect against COVID-19, but more
research is warranted.
2.6. Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disease of the brain, generally with
increased beta-amyloid plaque and tau protein deposition. The mechanisms whereby
vitamin D reduces the risk of AD include preventing amyloid development and clearing
it from the brain [89–91]. Most of the studies on the effects of vitamin D on the risk of
AD are observational. One from France followed 916 participants over 65 years old for
12 years [92]. A total of 117 dementia cases developed, of which 124 were AD. The adjusted
HR for AD compared to 25(OH)D concentrations >20 ng/mL was 2.17 (95% CI, 1.37 to 5.68)
for those with a 25(OH)D concentration between 12 and 25 ng/mL and 2.85 (95% CI, 1.36
to 5.97) for those with a 25(OH)D concentration <12 ng/mL.
A meta-analysis of six observational studies found the HR for AD for a 10 ng/mL
increase in 25(OH)D concentration of 0.83 (95% CI, 0.68 to 0.96) [93]. Another meta-analysis
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based on nine observational studies found that for 25(OH)D concentrations <20 ng/mL,
HR = 1.34 (95% CI, 1.13 to 1.60) [94]. A recent MR analysis based on data from the IGAP and
the UK Biobank found that genetically increased 25(OH)D concentrations were significantly
associated with reduced risks of AD [95].
2.7. All-Cause Mortality
Based on the effect of vitamin D on the major causes of death in developed countries,
it would be expected that there would be an inverse relationship between serum 25(OH)D
concentrations and subsequent all-cause mortality rate and this has been found using
meta-analyses; one conducted in 2012 used 14 prospective studies with 62,548 individuals found an RR of 0.69 (95% CI, 0.60 to 0.78) for 25(OH)D = 31 ng/mL vs. 11 ng/mL,
with no further decreases in mortality rates above 35 ng/mL [96]. Another meta-analysis
of 32 studies found that 25(OH)D values >30 ng/mL vs. <10 ng/mL had an RR for
survival of 1.9 (95% CI, 1.6 to 2.2) [97]. Another study from a European consortium of
26,916 individuals found that mortality rates increased with a lower individual participant
standardized 25(OH)D concentration in a cubic spline model adjusted for age, sex, and
BMI at baseline visit, compared to 30–40 ng/mL, HR = 1.06 (0.96 to 1.15) for 25(OH)D
concentrations reduced to 20–30 ng/mL, 1.14 (1.03–1.24) for 25(OH)D concentrations of
16–20 ng/mL, and reaching 1.29 (1.17–1.41) for 25(OH)D concentrations of 12–16 ng/mL,
and 1.72 (1.53–1.90) for 25(OH)D values <12 ng/mL [98]. In the 20-year Veterans Health
Administration study regarding myocardial infarction discussed above [8], patients achieving 25(OH)D concentrations of 20–30 ng/mL vs. <20 ng/mL had an all-cause mortality HR
of 0.59 (95% CI, 0.54 to 0.63), whereas in those achieving values >30 ng/mL, the mortality
HR was not further reduced at 0.61 (95% CI, 0.56 to 0.67).
A meta-analysis of 52 trials with 75,454 participants in vitamin D RCTs found that
supplementation was not associated with any changes in all-cause mortality rate (RR = 0.98
(95% CI, 0.95 to 1.02)) [99]. However, vitamin D supplementation did significantly reduce
cancer mortality rate (RR = 0.84 (95% CI, 0.74 to 0.95)) and subgroup analyses showed
all-cause mortality was significantly lower in trials giving vitamin D3 supplementation vs.
placebo (RR = 0.95 (95% CI, 0.91 to 1.00)) than in trials with vitamin D2 supplementation
vs. placebo (RR = 1.03 (95% CI, 0.98 to 1.09)). One problem with those meta-analyses was
that they did not have individual participant data for analysis, as was used for the acute
respiratory tract infection meta-analysis already referred to [74]. Another concern is that
trials with large cohorts used in those meta-analyses were made variously between 1996 to
2018, when 25(OH)D assays used were changing over [100,101], which inevitably adds a
degree of error to the reported meta-analyses.
3. Discussion
A summary of the findings reported in this review is given in Table 5. The optimal
25(OH)D concentration thresholds for these various outcomes range from 25 ng/mL to
60 ng/mL. All of these concentrations are higher than the 20 ng/mL recommended by the
Institute of Medicine based on its interpretation of requirements for bone health [102]. They
are in general agreement with the Endocrine Society’s recommendation of >30 ng/mL [103],
based on a more careful interpretation of a study of 25(OH)D concentrations and bone
mineralization [104]. They are also consistent with a recommendation of 30–50 ng/mL in
2018 for the pleiotropic (non-skeletal) effects of vitamin D [105].
The 25(OH)D concentration range of 30–40 ng/mL could generally be met by the
supplementation of 2000 to 4000 IU/day, which was reported as safe for all by the Institute
of Medicine [102]. Achieving concentrations above 40 ng/mL could take higher doses. The
Institute of Medicine noted that they did not have evidence that taking up to 10,000 IU/day
of vitamin D had any adverse effects, but set the upper tolerable level at 4000 IU/day out
of a concern for safety. The UK NIH also agrees that 4000 IU/day is safe (https://www.
nhs.uk/conditions/vitamins-and-minerals/vitamin-d/ accessed on 4 January 2021).
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Table 5. Optimal 25(OH)D concentrations for various health outcomes.
Outcome

Type of Evidence

Optimal 25OHD

Reference

All-cause mortality rate

Observational study of 25(OH)D concentration due to vitamin
D supplementation

>30 ng/mL

[8]

Alzheimer’s disease
and dementia

Meta-analysis of observational studies

>25 ng/ml

[93]

Breast cancer

Observational study of 25(OH)D concentration due to vitamin
D supplementation

>60 ng/mL

[33]

Colorectal cancer

Meta-analysis of observational studies

30–40 ng/mL

[34]

Cardiovascular disease

Observational study of the CVD mortality rate for CVD patients

>30 ng/mL

[9]

Myocardial infarction

Observational study of 25(OH)D concentration due to vitamin
D supplementation‘1n

>30 ng/mL

[8]

SARS-CoV-2 infection

Retrospective observational study

>50 ng/mL

[75]

COVID-19 mortality

Retrospective cohort study

>60 ng/mL

[82]

Diabetes mellitus type 2

RCT with an analysis of intratrial 25(OH)D for
prediabetes patients

>50 ng/mL

[70]

Gene expression

Clinical trial

>40 ng/mL

[45]

Hypertension

Observational study of 25(OH)D concentration due to vitamin
D supplementation

>40 ng/mL

[16]

Preterm delivery

Observational study of 25(OH)D concentration due to vitamin
D supplementation

>40 ng/mL

[106]

It has been shown experimentally that humans can produce between 10,000 and
25,000 IU of vitamin D through whole-body exposure to one minimal erythemal dose of
simulated sunlight, i.e., one instance of mid-day sun exposure without burning [107]. Thus,
doses to those levels should be considered inherently safe. Recent articles have reported
the safety results for high-dose vitamin D supplementation. One was a community-based,
open-access vitamin D supplementation program involving 3882 participants conducted
in Canada between 2013 and 2015 [108]. Participants took up to 15,000 IU/day of vitamin
D3 for between 6 and 18 months. The goal of the study was to determine vitamin D doses
required to achieve a 25(OH)D concentration >40 ng/mL. It was found that participants
with a normal BMI had to take at least 6000 IU/day of vitamin D, whereas overweight and
obese participants had to take 7000 IU/day and 8000 IU/day, respectively. Serum 25(OH)D
concentrations of up to 120 ng/mL were achieved without the perturbation of calcium
homeostasis or toxicity.
Another study involved 777 long-term hospitalized patients taking 5000 to 50,000 IU/day
of vitamin D3 [109]. Subsets of those taking 5000 IU/d achieved mean 25(OH)D concentrations of 65 ± 20 ng/mL after 12 months, whereas those taking 10,000 IU/day achieved
100 ± 20 ng/mL after 12 months. No patients who achieved 25(OH)D concentrations
of 40–155 ng/mL developed hypercalcemia, nephrolithiais (kidney stones), or any other
symptoms of vitamin D toxicity as the result of vitamin D supplementation.
Hypersensitivity to vitamin D can develop in people with sarcoidosis and some
other lymphatic disorders, causing hypercalcaemia and its complications from exposure to
sunshine alone or following supplementation. See the discussion regarding vitamin D and
sarcoidosis in this recent review [110].
Thus, given the multiple indications of significant health benefits from raising serum
25(OH)D concentrations above 30 or 40 ng/mL as well as the near absence of adverse
effects, significant improvements in health at the individual and population levels could
be achieved. Methods to achieve optimal health benefits could usefully begin with establishing effect thresholds for different disorders with reasonable certainty while allowing
for variations reported with obesity, diabetes, ethnicity, age or gender and by instituting
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programs to encourage and facilitate raising serum 25(OH)D concentrations through a
variety of approaches including sensible solar UVB exposure, vitamin D supplementation
and food fortification. A vitamin D fortification program of dairy products initiated in
Finland in 2003 eventually resulted in 91% of non-vitamin D supplement users reaching
25(OH)D concentrations >20 ng/mL [111], The rationale and plan for food fortification
with vitamin D, which was doubled in 2010, was outlined in 2018 [112].
As for future research, the most efficient way to determine the effects of vitamin D
supplementation seems to be to conduct observational studies of individual participants
who supplement with vitamin D3 . A concern regarding such observational studies is that
the controls might not be well matched to those supplementing with vitamin D. A way to
improve such studies is to use propensity score matching of both groups, as reported in
two recent vitamin D studies. One was an examination of the de novo use of vitamin D
after the diagnosis of breast cancer [113]. The other was in the study from Spain regarding
vitamin D3 or calcifediol supplementation and the risk of COVID-19 [88]. Using propensity
score matching in observational studies can elevate them to the level of RCTs in terms of
examining causality.
Types of Studies, Strengths and Weaknesses
Many types of studies are used to help determine whether a factor modifies disease
risks (incidence, survival, and/or mortality rates). A typical evidence pyramid published
in 2018 showed a hierarchy with in vitro studies at the bottom, progressing upward with
animal, ecological, cross-sectional, case-control studies, and randomized controlled trials
(RCTs) with meta-analyses of RCTs at its apex [114]. Although this pyramid is appropriate
for pharmaceutical drugs, it has various limitations when applied to nutrients. Not generally included in such pyramids is an understanding of the mechanisms by which a nutrient
or agent of interest works, though that is very important when considering causality for
vitamin D in each disorder of interest. For mechanisms regarding vitamin D, the reader
is referred to Vitamin D, 4th Edition [115] as well as pubmed.gov and scholar.google.com.
The main types of studies used for vitamin D are discussed here in the ascending order of
classic pyramidal evidence hierarchies.
Ecological studies consider populations defined geographically and use risk-modifying
factors and health outcome population averages; they can be either geographical or temporal. For example, the first indication that better provision of vitamin D reduced cancer
risks came from an ecological study of colon cancer mortality rates in the U.S. in relation
to annual solar radiation doses [17] and for reduction in cardiovascular disease (CVD)
risks from a study showing seasonality in CVD mortality rates [2] and from a similar
finding for epidemic influenza in 2006 [116]. The strengths of ecological studies include
the inclusion of large numbers of participants, that solar UVB doses have large latitudinal
gradients in middle-latitude countries and show large seasonal variations, and that many
risk-modifying factors can be used in the analysis as were used for cancer in 2006 in an
American ecological study that included alcohol consumption, Hispanic heritage, poverty
level, smoking, and urban/rural residence as well as July 1992 solar UVB doses [19]. On the
other hand, solar UVB is an important source of vitamin D, but is strongly associated with
solar UVA (320–400 nm) radiation which has other health effects such as liberating nitric
oxide from subcutaneous nitrogen compounds, which reduces arterial stiffness [117] and
thereby reduces blood pressure [118] and the risk of COVID-19 [119]. However, ecological
studies performed on post-2000 data generally fail to find inverse correlations between
solar UVB and cancer incidence or mortality rates, most likely because people are spending
less time in the sun, use more sunblock, are also more likely to be obese and no doubt also
because cancer survival rates are now much improved by more effective therapies [120].
Although ecological studies cannot establish causality in isolation, they can provide strong
support in combination with other types of studies.
Cross-sectional studies consider the relationship between many variables and health
status at one point in time, revealing associations but unable to establish causality since
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variables studied may be affected by the disease of interest. Nonetheless, they can provide
associational information for comparison with findings from other types of studies; for
example, a cross-sectional study of women recently diagnosed with breast cancer in Brazil
showed an inverse correlation between serum 25(OH)D concentration and factors used
to estimate prognosis and showed an association of low 25(OH)D with increased rates of
estrogen receptor-negative tumors [121].
Case-control studies involve measuring variables for those with a particular outcome
(cases) with similar individuals without that outcome [122]. The study can be either
retrospective, e.g., the history of solar UVB exposure, or contemporaneous with disease
incidence, (e.g., serum 25(OH)D concentration). An important strength of case-control
studies for cancer and all-cause mortality rate is that they generally provides concomitant
serum 25(OH)D concentrations, whereas prospective studies use blood samples from
the time of enrollment even though 25(OH)D concentrations change over time, thereby
reducing correlations of 25(OH)D with outcomes over time [26]. This effect is especially
important for breast cancer which can progress from undetectable to obvious very rapidly
and is one of only a few cancers with a pronounced seasonality of incidence [123].
There are several concerns about case-control studies. One is that controls may not
be well matched to cases. The way to overcome this concern is to use propensity score
matching as conducted in two recent vitamin D studies [88,113]. Another is that the disease
itself may affect serum 25(OH)D concentration as has been demonstrated with acute
inflammatory diseases (e.g., acute respiratory tract infections [27]) but not for undiagnosed
cancers, where inflammation is not generalized.
Prospective cohort studies generally enroll participants over short periods of time,
measure many variables of relevance and draw blood for later analysis, before following
participants, commonly over many years before outcome assessment and data analysis
using a nested case-control approach. The advantages include the inclusion of many
subjects that act as controls against which case risk can be assessed. An important limitation
is that variable values can change over time, including serum 25(OH)D concentrations [26].
However, the results of individual cohort studies can be combined for meta-analyses, which
often provide the strongest evidence for various health outcomes [124].
An important limitation of observational studies is that most participants have serum
25(OH)D concentrations between 10 and 40 ng/mL [125,126]. Most vitamin D is obtained
from solar UVB exposure plus some from animal-based food including meat, fish, eggs [127],
and vitamin D-fortified food [112], and supplements. However, the recommended vitamin D supplement value for adults in the U.S. is 600 IU/day up to 70 years of age and
800 IU/day for those over 70 years old [102]. According to changes in serum 25(OH)D
with supplementation [12], 600 IU/day can increase 25(OH)D by about 5.6 ng/mL, and
800 IU/day by 7.5 ng/mL.
Thus, most observational studies to date include few participants with 25(OH)D
concentrations >40 ng/mL unless they are supplementing with 1000 to 5000 IU/day
or more as is the case for the observational studies conducted by GrassrootsHealth.net
(accessed on 15 December 2021), as discussed [33,106].
Randomized controlled trials (RCTs) are considered the strongest type of evidence in
medical decision making, their strength being that they examine the effect of particular
substances and can, therefore, rule out many confounding factors. Unfortunately, vitamin
D differs from pharmaceutical drugs in that there are several sources including solar UVB
exposure, diet, and supplements, and that serum 25(OH)D concentration–health outcome
relationships are non-linear. As a result, vitamin D RCTs generally fail to confirm findings
from observational studies [128,129]. Robert Heaney outlined the guidelines for nutrient
trials, where the important factor is that nutrient concentration, e.g., 25(OH)D, should drive
both trial design and analysis and not the supplemental dosage [47,48]. As a result of using
RCT design guidelines evolved for testing pharmaceutical drug efficacy most vitamin D
RCTs have failed to find the beneficial effects of supplementation. The primary reasons
for such predictable failures include enrolling participants with 25(OH)D concentrations
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that are relatively high, using relatively low vitamin D doses that cannot raise 25(OH)D
values into the normal range, permitting participants (including controls) to take additional
supplements, not recognizing that participants may have different vitamin D responses [49]
and that there are different 25(OH)D thresholds for different health benefits.
Although not on the standard evidence pyramid, Mendelian randomization (MR)
studies are also suggested to be valuable for establishing causality for vitamin D for
various health outcomes. MR studies compare the estimated effect of SNPs associated
with variation in 25(OH)D concentrations on the health outcomes seen in large numbers of
participants, often up to 100,000. Although some MR studies report inverse correlations
between the SNPs increasing serum 25(OH)D and several health outcomes [130] such as
the incidence of multiple sclerosis [131] and ovarian cancer [132], no such effects were
seen for eight other types of cancer [133]. The primary reasons for MRA failure are
likely to include the fact that total SNP-induced variation in 25(OH)D has often been
less than 25(OH)D assay variance [134] and that genome-wide association studies’ (GWAS)
analyses of the total percentage of SNP effects are made on the 25(OH)D data as a whole,
although such data is non-linear with much of it lying in the low and high plateaus of the
25(OH)D–health outcome relationships, a problem that the GWAS analysis of 25(OH)D
data stratified for different ranges of 25(OH)D efficacy might overcome [135]. That this is
the case for mortality rates was shown in two recent articles, one [10] where GWAS serum
25(OH)D concentration was stratified at <10 ng/mL, 10–20 ng/mL, 20–30 ng/mL, and
>30 ng/mL and significantly increased risk was only present at 25(OH)D <10 ng/mL for
all-cause mortality, cardiovascular mortality, and non-CVD and non-cancer mortality with
trends for increases in risk for stroke and cancer mortality. The other [12], using genetic
increases in serum 25(OH)D calculated for 100 equal strata of measured serum 25(OH)D
showed similar results for CVD with risk reduction for increases in 25(OH)D values up to
~20 ng/mL.
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